MaxCyte: Expanded prospects for CARMA
MaxCyte has confirmed that its CARMA Cell Therapies subsidiary will expand its phase I clinical trial of MCY-M11, its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers.
This is a natural progression based on promising preliminary data from the study presented at the virtual meeting of the American Society of Clinical Oncology (ASCO) in May.
The expansion of the study will add a new parallel cohort, that will receive preconditioning treatment and this factor plus the extension of the trial to include multiple treatment cycles are factors that can potentially enhance the efficacy of MCY-M11.
Quick facts: MaxCyte Inc
Price: 616 GBX
Market Cap: £475.31 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE